Related references
Note: Only part of the references are listed.Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Antonio Omuro et al.
NEURO-ONCOLOGY (2023)
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim et al.
NEURO-ONCOLOGY (2022)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2022)
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
J. Bryan Iorgulescu et al.
CLINICAL CANCER RESEARCH (2021)
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
John H. Strickler et al.
CLINICAL CANCER RESEARCH (2021)
What is the burden of proof for tumor mutational burden in gliomas?
Mustafa Khasraw et al.
NEURO-ONCOLOGY (2021)
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Matthias Gromeier et al.
NATURE COMMUNICATIONS (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
Hao-Wen Sim et al.
NEURO-ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat et al.
NATURE (2020)
Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment
Anaelle A. Dumas et al.
EMBO JOURNAL (2020)
Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators
Katayoun Ayasoufi et al.
BRAIN (2020)
PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
Zhiyuan Zhu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Curtis H. Kugel et al.
CLINICAL CANCER RESEARCH (2018)
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
Anton Uryvaev et al.
MEDICAL ONCOLOGY (2018)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Amber J. Giles et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Rimas V. Lukas et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Pakawat Chongsathidkiet et al.
NATURE MEDICINE (2018)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria
Lakshmi Nayak et al.
NEURO-ONCOLOGY (2017)
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Benjamin M. Ellingson et al.
NEUROTHERAPEUTICS (2017)
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James R. Perry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immune Checkpoint Inhibitors in Gliomas
Aaron C. Tan et al.
CURRENT ONCOLOGY REPORTS (2017)
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma
Abhishek D. Garg et al.
ONCOIMMUNOLOGY (2017)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
The promising role of nivolumab in renal cell cancers
Kanika Gupta et al.
CANCER BIOLOGY & THERAPY (2016)
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial
Linda Dirven et al.
EUROPEAN JOURNAL OF CANCER (2015)
Nivolumab for treating non-small cell lung cancer
Nicolas Guibert et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
Martin J. B. Taphoorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Scott D. Brown et al.
GENOME RESEARCH (2014)
Exomics and immunogenics Bridging mutational load and immune checkpoints efficacy
Stephane Champiat et al.
ONCOIMMUNOLOGY (2014)
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
Sara Fritzell et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients
K. L. McDonald et al.
EUROPEAN JOURNAL OF CANCER (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation
Cristian Tomasetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity
Guangjin Li et al.
NATURE MEDICINE (2012)
Signal inhibition by the dual-specific phosphatase 4 impairs T cell-dependent B-cell responses with age
Mingcan Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Age-related changes in CD8 T cell homeostasis and immunity to infection
Janko Nikolich-Zugich et al.
SEMINARS IN IMMUNOLOGY (2012)
Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Stuart A. Grossman et al.
CLINICAL CANCER RESEARCH (2011)
Survival comparison between glioblastoma multiforme and other incurable cancers
B. Tran et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Francis Rodier et al.
NATURE CELL BIOLOGY (2009)
Thymic involution and immune reconstitution
Heather E. Lynch et al.
TRENDS IN IMMUNOLOGY (2009)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Age-related changes in lymphocyte development and function
PJ Linton et al.
NATURE IMMUNOLOGY (2004)
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations
OL Chinot et al.
CANCER (2004)
Rational approaches to human cancer immunotherapy
ID Davis et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Share Paper
